Clear Harbor Asset Management LLC Purchases Shares of 11,000 Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Clear Harbor Asset Management LLC bought a new position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVAFree Report) during the fourth quarter, Holdings Channel reports. The firm bought 11,000 shares of the biotechnology company’s stock, valued at approximately $89,000.

A number of other hedge funds also recently made changes to their positions in the company. Lazard Asset Management LLC lifted its position in shares of Iovance Biotherapeutics by 38.5% in the first quarter. Lazard Asset Management LLC now owns 3,357 shares of the biotechnology company’s stock worth $55,000 after buying an additional 934 shares in the last quarter. Baird Financial Group Inc. lifted its position in shares of Iovance Biotherapeutics by 3.7% in the first quarter. Baird Financial Group Inc. now owns 27,545 shares of the biotechnology company’s stock worth $459,000 after buying an additional 995 shares in the last quarter. Rockefeller Capital Management L.P. lifted its position in shares of Iovance Biotherapeutics by 3.8% in the second quarter. Rockefeller Capital Management L.P. now owns 37,758 shares of the biotechnology company’s stock worth $266,000 after buying an additional 1,385 shares in the last quarter. Diversified Trust Co raised its position in Iovance Biotherapeutics by 12.3% during the fourth quarter. Diversified Trust Co now owns 13,512 shares of the biotechnology company’s stock valued at $110,000 after purchasing an additional 1,481 shares during the period. Finally, American Century Companies Inc. raised its position in Iovance Biotherapeutics by 0.5% during the first quarter. American Century Companies Inc. now owns 319,310 shares of the biotechnology company’s stock valued at $1,951,000 after purchasing an additional 1,649 shares during the period. 77.03% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Merrill A. Mcpeak acquired 250,000 shares of Iovance Biotherapeutics stock in a transaction on Tuesday, February 20th. The shares were bought at an average cost of $9.15 per share, for a total transaction of $2,287,500.00. Following the acquisition, the director now directly owns 320,150 shares of the company’s stock, valued at approximately $2,929,372.50. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 10.40% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on IOVA shares. StockNews.com upgraded Iovance Biotherapeutics to a “sell” rating in a research report on Friday, February 2nd. HC Wainwright restated a “buy” rating and set a $32.00 price objective on shares of Iovance Biotherapeutics in a research report on Thursday, February 29th. Truist Financial restated a “buy” rating and set a $17.00 price objective on shares of Iovance Biotherapeutics in a research report on Wednesday, December 27th. Wells Fargo & Company raised their price target on Iovance Biotherapeutics from $22.00 to $25.00 and gave the stock an “overweight” rating in a research note on Friday, March 1st. Finally, JMP Securities raised their price target on Iovance Biotherapeutics from $18.00 to $25.00 and gave the stock a “market outperform” rating in a research note on Tuesday, February 20th. One analyst has rated the stock with a sell rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, Iovance Biotherapeutics currently has an average rating of “Moderate Buy” and an average price target of $24.64.

Get Our Latest Stock Report on Iovance Biotherapeutics

Iovance Biotherapeutics Stock Up 5.1 %

IOVA opened at $14.82 on Friday. The stock’s fifty day moving average is $12.45 and its two-hundred day moving average is $8.09. The company has a market capitalization of $4.14 billion, a P/E ratio of -7.88 and a beta of 0.63. Iovance Biotherapeutics, Inc. has a 52 week low of $3.21 and a 52 week high of $18.33.

Iovance Biotherapeutics (NASDAQ:IOVAGet Free Report) last released its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.01). The business had revenue of $0.48 million during the quarter, compared to the consensus estimate of $1.44 million. During the same quarter in the prior year, the firm earned ($0.64) EPS. Equities analysts anticipate that Iovance Biotherapeutics, Inc. will post -1.4 earnings per share for the current year.

Iovance Biotherapeutics Company Profile

(Free Report)

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.

Further Reading

Want to see what other hedge funds are holding IOVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iovance Biotherapeutics, Inc. (NASDAQ:IOVAFree Report).

Institutional Ownership by Quarter for Iovance Biotherapeutics (NASDAQ:IOVA)

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.